Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Gilead receives positive CHMP opinions under accelerated review from EMA for twice-yearly lenacapavir for HIV prevention: Foster City, California Saturday, July 26, 2025, 13:00 Hr ...

Sobi® (STO: SOBI) and Ionis Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.

KalVista on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers Ekterly in people ages 12 and older for the symptomatic treatment of ...

Gilead on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers lenacapavir for use as pre-exposure prophylaxis, or PrEP, to reduce ...

EMA committee recommends marketing approval of Pfizer & BioNTech’s LP.8.1-adapted Covid-19 vaccine: New York Saturday, July 26, 2025, 10:00 Hrs [IST] Pfizer Inc. and BioNTech SE ...

EMA's CHMP backs key drugs from KalVista, Biogen & Ionis for conditions like hereditary angioedema & postpartum depression.

Gilead (GILD) wins the backing of an EU panel for lenacapavir, its twice-yearly injectable for prevention of HIV in ...

Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

Prilenia Therapeutics B.V. and Ferrer today announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...